$Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma$
Código QR

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

The proteasome is crucial for the degradation of intracellular proteins and plays an important role in mediating a number of cell survival and progression events by controlling the levels of key regulatory proteins such as cyclins and caspases in both normal and tumor cells. However, compared to nor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam, Gayathri N. Silva
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	multiple myeloma proteasome inhibitors carfilzomib anti-tumor effect combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1539749653ac4a9da82be0000528dd75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1539749653ac4a9da82be0000528dd75
record_format	dspace
spelling	oai:doaj.org-article:1539749653ac4a9da82be0000528dd752021-11-10T12:55:33ZCarfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma2234-943X10.3389/fonc.2021.740796https://doaj.org/article/1539749653ac4a9da82be0000528dd752021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.740796/fullhttps://doaj.org/toc/2234-943XThe proteasome is crucial for the degradation of intracellular proteins and plays an important role in mediating a number of cell survival and progression events by controlling the levels of key regulatory proteins such as cyclins and caspases in both normal and tumor cells. However, compared to normal cells, cancer cells are more dependent on the ubiquitin proteasome pathway (UPP) due to the accumulation of proteins in response to uncontrolled gene transcription, allowing proteasome to become a potent therapeutic target for human cancers such as multiple myeloma (MM). Up to date, three proteasome inhibitors namely bortezomib (2003), carfilzomib (2012) and ixazomib (2015) have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed and/or refractory MM. This review mainly focuses on the biochemical properties, mechanism of action, toxicity profile and pivotal clinical trials related to carfilzomib, a second-generation proteasome inhibitor that binds irreversibly with proteasome to overcome the major toxicities and resistance associated with bortezomib.Shansa Pranami E. JayaweeraSacheela Prasadi Wanigasinghe KanakanamgeDharshika RajalingamGayathri N. SilvaFrontiers Media S.A.articlemultiple myelomaproteasome inhibitorscarfilzomibanti-tumor effectcombination therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple myeloma proteasome inhibitors carfilzomib anti-tumor effect combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	multiple myeloma proteasome inhibitors carfilzomib anti-tumor effect combination therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shansa Pranami E. Jayaweera Sacheela Prasadi Wanigasinghe Kanakanamge Dharshika Rajalingam Gayathri N. Silva Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
description	The proteasome is crucial for the degradation of intracellular proteins and plays an important role in mediating a number of cell survival and progression events by controlling the levels of key regulatory proteins such as cyclins and caspases in both normal and tumor cells. However, compared to normal cells, cancer cells are more dependent on the ubiquitin proteasome pathway (UPP) due to the accumulation of proteins in response to uncontrolled gene transcription, allowing proteasome to become a potent therapeutic target for human cancers such as multiple myeloma (MM). Up to date, three proteasome inhibitors namely bortezomib (2003), carfilzomib (2012) and ixazomib (2015) have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with relapsed and/or refractory MM. This review mainly focuses on the biochemical properties, mechanism of action, toxicity profile and pivotal clinical trials related to carfilzomib, a second-generation proteasome inhibitor that binds irreversibly with proteasome to overcome the major toxicities and resistance associated with bortezomib.
format	article
author	Shansa Pranami E. Jayaweera Sacheela Prasadi Wanigasinghe Kanakanamge Dharshika Rajalingam Gayathri N. Silva
author_facet	Shansa Pranami E. Jayaweera Sacheela Prasadi Wanigasinghe Kanakanamge Dharshika Rajalingam Gayathri N. Silva
author_sort	Shansa Pranami E. Jayaweera
title	Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
title_short	Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
title_full	Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
title_fullStr	Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
title_full_unstemmed	Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
title_sort	carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1539749653ac4a9da82be0000528dd75
work_keys_str_mv	AT shansapranamiejayaweera carfilzomibapromisingproteasomeinhibitorforthetreatmentofrelapsedandrefractorymultiplemyeloma AT sacheelaprasadiwanigasinghekanakanamge carfilzomibapromisingproteasomeinhibitorforthetreatmentofrelapsedandrefractorymultiplemyeloma AT dharshikarajalingam carfilzomibapromisingproteasomeinhibitorforthetreatmentofrelapsedandrefractorymultiplemyeloma AT gayathrinsilva carfilzomibapromisingproteasomeinhibitorforthetreatmentofrelapsedandrefractorymultiplemyeloma
_version_	1718439956068696064

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Ejemplares similares